Simuni T, on behalf of the Parkinson Study Group. A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results. AAN 2019.
ECTRIMS 2015 video update Bouma: Parallel Session 2 New challenges in clinical trial design
jun 2017